New hope for blood cancer patients: first human trial of experimental drug begins
NCT ID NCT07220616
Summary
This is the first human trial testing an experimental drug called DS3790a for people with various blood cancers. The study aims to find safe doses and see if the drug, given alone or with other treatments, can help control these cancers. Researchers will enroll 420 adults with blood cancers to monitor side effects and early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
RECRUITINGNagoya, 464-8681, Japan
Contact
-
Research Site
RECRUITINGNew York, New York, 10065, United States
Contact
-
Research Site
RECRUITINGTokyo, 104-0045, Japan
Contact
-
Research Site
RECRUITINGTokyo, 135-8550, Japan
Contact
Conditions
Explore the condition pages connected to this study.